Quick orientationEvidence update: 6 October 2026
What is NAD+?
NAD+ is not actually a peptide. It is a coenzyme that cells use constantly in energy metabolism and redox reactions, and it also feeds enzymes involved in DNA repair and cellular signalling.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Human studies examine NAD metabolome changes with precursors and, more sparsely, direct administration.
What the mechanism suggests
Nicotinamide adenine dinucleotide is a coenzyme central to redox metabolism; it is not itself a peptide.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Nicotinamide adenine dinucleotide is a coenzyme central to redox metabolism; it is not itself a peptide.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Six-hour IV NAD+ metabolism pilot — 2019
Human metabolic pilot · continuous 3 μmol/min IV infusion for 6 hoursPlasma NAD+ and measured metabolites did not rise for the first two hours; later urinary NAD+ and methyl-nicotinamide increased. The study mapped metabolism rather than testing energy, cognition or longevity benefits.
IV NAD+ has human pharmacology data, but popular wellness outcomes were not what this study proved.
What it doesn't prove: Pilot metabolic study without a placebo-controlled clinical efficacy endpoint.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| IV metabolome pilot | 750 mg NAD+ IV over 6 hours (~2 mg/min) | Single 6-hour infusion | Fixed infusion rate | 8 treated participants |
| Clinical-context note | 750 mg was selected because it reflected a common clinic infusion regimen, not because a dose-ranging trial established it | — | — | Pilot pharmacometabolomic study |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| IV clinic lower | ~250–500 mg IV | 1–4 h, intermittent courses | Often slower first infusion | Clinic convention |
| IV clinic higher | ~750–1000 mg IV | Several hours | Rate adjusted for tolerability | Clinic convention |
| SC community | ~20–100 mg per administration | Several times weekly to daily | Often starts lower | Community/clinic; no standardized trial dose |
NAD+ is a coenzyme, not a peptide. The 750 mg human pilot is useful pharmacology evidence but does not validate the very broad IV/SC wellness protocols.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Claims for energy, cognition and anti-ageing often run ahead of outcome evidence.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
IV NAD+ has human pharmacology data, but popular wellness outcomes were not what this study proved.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.